ArticleCNS neuroscience & therapeutics2012
Cerebrospinal fluid biomarkers in Alzheimer's disease and geriatric depression: preliminary findings from Brazil.
Article in CNS neuroscience & therapeutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Association of amyloid-beta with depression or depressive symptoms in older adults without dementia: a systematic review and meta-analysis.Translational psychiatry · 2024Pooled it
- Plasma and cerebrospinal fluid amyloid-β levels in late-life depression: A systematic review and meta-analysis.Journal of psychiatric research · 2015Pooled it
- Biomarker profiles in late-life depression and Alzheimer's disease across and beyond the A/T/N framework: A scoping review.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
- Biomarkers of neurodegeneration across the Global South.The lancet. Healthy longevity · 2024Review
- Differential Diagnosis Findings Between Alzheimer's Disease and Major Depressive Disorder: A Review.Psychiatry and clinical psychopharmacology · 2022Article
- Mental Illness and Amyloid: A Scoping Review of Scientific Evidence over the Last 10 Years (2011 to 2021).Brain sciences · 2021Article
- Elevated Glutamate and Glutamine Levels in the Cerebrospinal Fluid of Patients With Probable Alzheimer's Disease and Depression.Frontiers in psychiatry · 2018Article
- Cortical Amyloid β Deposition and Current Depressive Symptoms in Alzheimer Disease and Mild Cognitive Impairment.Journal of geriatric psychiatry and neurology · 2016Article
- d-serine levels in Alzheimer's disease: implications for novel biomarker development.Translational psychiatry · 2015Article
- Reduced cerebrospinal fluid levels of brain-derived neurotrophic factor is associated with cognitive impairment in late-life major depression.The journals of gerontology. Series B, Psychological sciences and social sciences · 2014Article
- Progress update: fluid and imaging biomarkers in Alzheimer's disease.Biological psychiatry · 2014Review
- Depressive Symptoms in Clinical and Incipient Alzheimer's Disease.Neurodegenerative disease management · 2013Article
- Depressive disorders in the elderly and dementia: An update.Dementia & neuropsychologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsDepression is a highly prevalent disorder in the elderly and one of the risk factors for developing dementia. The present study involves patients with Alzheimer's disease (AD), geriatric major depressive disorder (MDD) and cognitively healthy controls aiming to compare baseline cerebrospinal fluid (CSF) biomarkers.
methodsThe study included 52 patients with more than 60 years of age with a diagnosis of MDD, AD, and healthy controls. All individuals underwent a medical history, physical, and neurologic examination, laboratory tests and neuropsychological assessment to rule out any clinical diseases or disorders. Measurement of CSF P-tau(181) , T-tau, and Aβ42 was performed using commercial assays (ELISA).
resultsCSF Aβ42 levels of depressed patients and normal controls were significantly higher than in AD. There was not any significant difference in measures of P-tau among the groups. T-tau, however, showed to be significantly different among the groups, with higher measures in AD group. Higher levels of P-tau were observed in four MDD patients compared with controls.
conclusionCSF Aβ42, T-tau, and P-tau levels may differentiate between AD and depression in a Brazilian sample.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.